GEN vs GWRE

GEN presents a stark contrast between strong growth fundamentals and deteriorating financial health and market sentiment. While the Piotroski F-Score of 4/9 indicates a stable but mediocre health profile, the current ratio of 0.47 and high debt-to-equity ratio of 3.63 signal significant short-term liquidity risks. Valuation is highly attractive on a forward basis (Forward P/E 6.40, PEG 0.47), but this is heavily offset by a bearish technical trend (0/100) and insider selling. The stock is currently trading near its 52-week low, suggesting the market is pricing in balance sheet fragility over growth potential.

GWRE demonstrates strong fundamental health with a Piotroski F-Score of 7/9 and robust liquidity (Current Ratio 2.93). While the stock trades at a massive premium to its Graham Number ($29.79) and Intrinsic Value ($15.47), its PEG ratio of 0.85 suggests that its aggressive growth trajectory may justify a higher valuation. However, the combination of a severe short-term price collapse (-46% in 6 months) and consistent bearish insider selling by the CEO creates significant near-term risk. The stock is currently a battle between strong operational execution and poor market sentiment/valuation disconnect.